Anlotinib Retrospective Study for Esophageal Cancer

Sponsor
Feng Wang (Other)
Overall Status
Completed
CT.gov ID
NCT05303740
Collaborator
(none)
300
1
37.9
7.9

Study Details

Study Description

Brief Summary

The efficacy of anlotinib in the treatment of esophageal cancer has been confirmed. The purpose of this study was to retrospectively observe the efficacy and safety of anlotinib in the first and second line of advanced esophageal cancer in the real world.

Condition or Disease Intervention/Treatment Phase

Study Design

Study Type:
Observational
Actual Enrollment :
300 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Efficacy and Safety of Anlotinib in the First-line or Second-line Treatment of Locally Advanced or Metastatic Esophageal Cancer in China, a Retrospective, Multicenter, Real-world Study
Actual Study Start Date :
Jan 1, 2019
Actual Primary Completion Date :
Mar 1, 2022
Actual Study Completion Date :
Mar 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Anlotinib

Drug: Anlotinib
This is an observational study.

Outcome Measures

Primary Outcome Measures

  1. PFS [From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months]

    Progression Free Survival

Secondary Outcome Measures

  1. OS [From date of admission until the date of death from any cause, assessed up to 24 months]

    Overall Survival

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Esophageal cancer diagnosed pathologically or clinically

  • Patients who use anlotinib alone, or combined with chemoradiotherapy, or plus PD-1 inhibitors in first-line or second-line treatment

Exclusion Criteria:

None

Contacts and Locations

Locations

Site City State Country Postal Code
1 The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan China 450000

Sponsors and Collaborators

  • Feng Wang

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Feng Wang, Chief physician, The First Affiliated Hospital of Zhengzhou University
ClinicalTrials.gov Identifier:
NCT05303740
Other Study ID Numbers:
  • L2021-Y348-001
First Posted:
Mar 31, 2022
Last Update Posted:
Mar 31, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 31, 2022